Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 344-355

  Soyland E ^a   Heier, Ingvild ^a,b   Rodriguez Gallego C ^c   Mollnes, T E ^a,d   Johansen, F E ^a,b   Holven, K B ^b   Halvorsen, B ^a,d   Aukrust, P ^a,d   Jahnsen, F L ^a,b   De La Rosa Carrillo, D ^a   Krogstad, A L ^a   Nenseter, M S ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23P19; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DERMIS; DISEASE SEVERITY; EPIDERMIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; LANGERHANS CELL; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; SKIN; SKIN BIOPSY; SKIN DEFECT; SPAIN; SUN EXPOSURE; T LYMPHOCYTE SUBPOPULATION; ULTRAVIOLET IRRADIATION;

ADULT; AGED; BIOPSY; CYTOKINES; FEMALE; HELIOTHERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; LANGERHANS CELLS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 79551486070     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10149.x     Document Type: Article

References (37)

1. Lebwohl M,. Psoriasis. Lancet 2003; 361: 1197-204.
2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
3. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
4. Nickoloff BJ, Qin JZ, Nestle FO,. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007; 33: 45-56.
5. Nickoloff BJ, Xin H, Nestle FO, et al. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007; 25: 568-73.
6. Gisondi P, Girolomoni G,. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007; 6: 515-19.
7. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
8. van Beelen AJ, Teunissen MB, Kapsenberg ML, et al. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 2007; 7: 374-81.
9. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-94.
10. Haider AS, Lowes MA, Suarez-Farinas M, et al. Identification of cellular pathways of "Type 1," Th17 T Cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180: 1913-20.
11. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
12. Blauvelt A,. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128: 1064-7.
13. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-92.
14. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-40.
15. Papp KA,. Monitoring biologics for the treatment of psoriasis. Clin Dermatol 2008; 26: 515-21.
16. Shani J, Harari M, Hristakieva E, et al. Dead-Sea climatotherapy versus other modalities of treatment for psoriasis: comparative cost-effectiveness. Int J Dermatol 1999; 38: 252-62.
17. Hodak E, Gottlieb AB, Segal T, et al. Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation. J Am Acad Dermatol 2003; 49: 451-7.
18. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10: i-iv.
19. Norval M, McLoone P, Lesiak A, et al. The effect of chronic ultraviolet radiation on the human immune system. Photochem Photobiol 2008; 84: 19-28.
20. Maeda A, Beissert S, Schwarz T, et al. Phenotypic and functional characterization of ultraviolet radiation-induced regulatory T cells. J Immunol 2008; 180: 3065-71.
21. Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007; 8: 285-93.
22. Cantorna MT, Zhu Y, Froicu M, et al. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80: 1717S-20S.
23. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
24. Fitzpatrick TB,. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869-71.
25. Nilsen LT, Soyland E, Krogstad AL,. Estimated ultraviolet doses to psoriasis patients during climate therapy. Photodermatol Photoimmunol Photomed 2009; 25: 202-8.
26. Ghoreschi K, Weigert C, Rocken M,. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007; 25: 574-80.
27. Sigmundsdottir H, Gudjonsson JE, Valdimarsson H,. The effects of ultraviolet B treatment on the expression of adhesion molecules by circulating T lymphocytes in psoriasis. Br J Dermatol 2003; 148: 996-1000.
28. Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999; 189: 711-18.
29. Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995; 182: 2057-68.
30. Kolgen W, Both H, van Weelden H., et al. Epidermal Langerhans cell depletion after artificial ultraviolet B irradiation of human skin in vivo: apoptosis versus migration. J Invest Dermatol 2002; 118: 812-17.
31. Piskin G, Tursen U, Sylva-Steenland RM, et al. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers-IL-12, IL-18 and IL-23. Exp Dermatol 2004; 13: 764-72.
32. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-11.
33. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159: 1092-102.
34. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009; 129: 79-88.
35. Schwarz T,. Mechanisms of UV-induced immunosuppression. Keio J Med 2005; 54: 165-71.
36. Gordon KB, Bonish BK, Patel T, et al. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005; 153: 945-53.
37. Cumberbatch M, Singh M, Dearman RJ, et al. Impaired Langerhans cell migration in psoriasis. J Exp Med 2006; 203: 953-60.